The Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for patients with locally advanced or ...

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

Oct. 17, 2024 — Scientists developed a way of using artificial intelligence to check for skin cancer with the AI tool, which was trained on data from 53,601 skin lesions from 25,105 patients ...

The findings suggest a new drug target that could lead to therapies for deadly metastatic skin cancer ... cells before they ...

"We know how to cure primary tumors—with surgery, and sometimes with chemotherapy and radiation. Metastatic disease ...

BMs should be distinguished from other CNS metastases. The term BM should be limited to the focal seeding of the brain parenchyma (parenchymal BMs) and not used in the case of secondary lesions ...

all patients developing positive DTH reactions had a clinical response of complete or partial rejection of metastatic lesions. Patient 2, who did not develop a positive skin reaction after ...

Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.